.
Isolates of various mycobacterial species tested with esat-6 restrictionfragment length polymorphism. 
NOTE.
BCG, bacille Calmette-Guérin; RIVM no., identification code of the collection of nontuberculous mycobacteria at the National Institute of Public Health and the Environment. NLA000001495 1995  I  I  I  I  I  Hot tap water Czech Republic  NLA000001049 2000  II  II  II  II  II  Human (S)  The Netherlands  NLA000001469 1994  II  II  II  II  II  Environment  Italy  NLA000001471 1994  II  II  II  II  II  Environment  Italy  NLA000001454 1991  III  III  III  III  III  Tap water  Belgium  NLA000001493 1995  III  ND  ND  IIIb  IIIb  Tap water  Germany  NLA000001457 1993  IV  IV  IV  IV  IV  Biofilm  Germany  NLA000001458 1993  IV  IV  IV  IV  IV  Tap water  Germany  NLA000001470 1994  IV  ND  ND  IV  IV  Environment  Italy  NLA000001459 1995  V  V  V  V  V  Tap water  Belgium  NLA000001464 1995  V  V  V  V  V  Tap water  Belgium  NLA000001465 1996  V  V  V  V  V  Tap water  Belgium  NLA000001461 
NOTE. ND, not determined; MPTR, major polymorphic tandem repeat; RIVM no., identification code of the collection of nontuberculous mycobacteria at the National Institute of Public Health and the Environment; RFLP, restriction-fragment length polymorphism. a Each capital denotes a different patient; 2 isolates from patients F, G, and K were included.
Characterization of the ITS subtypes. ITS subtypes were determined by use of INNOLiPA Mycobacteria (Innogenetics), a DNA probe test that targets the 16S 23S rDNA ITS sequence, as described elsewhere [27] . This commercially available assay differentiates between M. kansasii group I and II and detects group III, IV, and V without discriminating among these ITS types. To differentiate between the latter types, a research LiPA strip (strip K) was used (Innogenetics; data not shown) that contained specific DNA probes for each ITS type. The M. kansasii isolates included all 5 genotypes.
Culture condition. M. kansasii isolates were kept at -70°C in aliquots in Middlebrook 7H9 supplemented with oleic acid albumin dextrose catalase and 15% glycerol until testing. Cultures were grown on Löwenstein-Jenssen medium at 35.5°C until sufficient growth was obtained for Western blotting and DNA isolation.
Southern-blot analysis.
Southern blots of the M. kansasii isolates were prepared as described elsewhere [25] . Briefly, DNA isolation was performed by use of the N-cetyl-N,N,N,-trimethyl ammonium bromide method. The purified DNA was digested with the restriction enzyme PvuII and subjected to electrophoresis. A mixture of a PvuII-digested supercoiled DNA ladder (Invitrogen) and HaeIII-digested phiX174 DNA was used as an internal DNA size marker. The DNA fragments were transferred to a DNA membrane. The DNA membranes were hybridized with the major polymorphic tandem repeat (MPTR) [26] , and complete esat-6 and cfp-10 genes were hybridized with the enhanced chemiluminescence (ECL) direct nucleic acid labeling and detection systems (Amersham Biosciences Europe). The probes of the esat-6 and cfp-10 genes were obtained by PCR by use of M. tuberculosis H 37 Rv DNA as target and were purified as described below. The primer sets used were Esa-12 CAT GAC AGA GCA GCA GTG and Esa-303 5 -GCC CTA TGC GAA CAT CCC-3 [11] for esat-6 and opBR78 5 -GTA GCC CGG GAT GGC AGA GAT GAA GAC CGA TGC C-3 and opBR103 5 -TCA GAA GCC CAT TTG CGA GGA CAG C-3 for cfp-10. Computer-assisted analysis of the restriction-fragment length polymorphism (RFLP) patterns was done by use of BioNumerics software (version 3.0; Applied Maths).
Nucleotide sequencing.
Amplification of the esat-6 and cfp-10 genes was performed by use of 10 pmol of the primers described above. The primers, together with 50 ng of purified DNA, were added to 12.5 L of HotStarTaq Master mix (Qiagen), and the reaction volume was adjusted to 25 L with Milli-Q water (Millipore). The amplification mixture was subjected to initial denaturation for 3 min at 96°C; followed by 30 cycles at 96°C for 1 min, 60°C for 2 min, and 72°C for 3 min; and a final extension period at 72°C for 6 min. The PCR products were purified by use of a PCR purification kit (Qiagen). The nucleotide sequence of the esat-6 and cfp-10 genes was determined on both strands by direct sequencing of the PCR products on an 
Western-blot analysis.
Lysates of 2 clinical and 4 environmental M. kansasii isolates were obtained after culturing in modified Sauton medium at 37°C on an orbital shaker, as described elsewhere [28] . Bacteria were harvested after centrifugation, and the bacterial pellet was washed once in PBS (pH 7.4) and resuspended in a suspension that contained equal volumes of 0.1-mm glass beads and PBS with 1 mmol/L phenylmethylsulfonyl fluoride. The bacteria were thereafter lysed on a Mini-BeadBeater (Biospec Products), and the protein concentration was determined by the bicinchoninic acid method (Pierce). Ten micrograms of each protein lysate was applied for SDS-PAGE and Western-blot analysis, as described elsewhere [12] . As a reference, a short-term culture filtrate of M. tuberculosis was included [28] . ESAT-6 was detected by the monoclonal antibody HYB 76-8 [29] , and CFP-10 was detected by the rabbit antibody K8493 raised against recombinant CFP-10, as described elsewhere [30] . The ECL Western-blotting system (Amersham Biosciences) was used for chemiluminescence detection of Western blots.
RESULTS

esat-6 RFLP in different mycobacterial species.
Hybridization of a Southern blot containing DNA of a large variety of mycobacterial species with the esat-6 probe showed that the esat-6 or "esat-6 like" gene was present in M. tuberculosis, M. kansasii (MKA-I), M. kansasii gastrii (MKA-IV), and 2 of 5 M. marinum isolates (table 1) . A weak but positive band was observed in 1 of 2 Mycobacterium gordonae isolates. The isolates were retested, with identical results. When the cfp-10 probe was used, all 5 M. marinum isolates gave a positive band. No esat-6 or esat-6 like genes were found in Mycobacterium avium hominissuis [31] , M. avium avium, M. avium paratuberculosis, Mycobacterium malmoënse, Mycobacterium xenopi, Mycobacterium chelonei abscessus, Mycobacterium peregrinum, Mycobacterium fortuitum, or M. bovis BCG (Pasteur), confirming previous findings [11] . A representative selection of these findings is presented in figure 1 . Southern-blot analysis of the esat-6 and cfp-10 genes demonstrated that a clear distinction could be made between clinical and environmental isolates of M. kansasii that corresponded to MPTR pattern distribution among the MKA genotypes. The MPTR-RFLP and esat-6 RFLP of a representative selection of isolates is shown in figure 2 . Within each genotype, the pattern of the remaining isolates listed in table 2 were identical. For all isolates, the results obtained with cfp-10 RFLP were identical to those of the esat-6 RFLP.
Figure 2
Southern-blot analysis by use of the esat-6 probe of Mycobacterium tuberculosis and major polymorphic tandem-repeat (MPTR) fingerprinting in relation to the Mycobacterium kansasii genotype, according to the 16S 23S intergenic spacer region. Similar results were obtained with the cfp-10 probe (data not shown).
Gene sequencing.
Of the 5 different genotypes of M. kansasii, the nucleotide sequences of the PCR products of the esat-6 and cfp-10 genes were determined, including at least 2 isolates per genotype ( figure 3A and 3B) . Within each genotype, the sequences of esat-6 and cfp-10 genes were always 100% identical, except for MKA-III. Comparison of the 2 MKA-III genotype isolates that were sequenced showed a 1-bp difference in both the esat-6 and cfp-10 genes. When genotype MKA-I was used as a reference, the DNA sequences of the esat-6 gene (285 bp) differed between 0.3% (1 bp in MKA-IV) and 2.1% (6 bp in MKA-III), whereas the M. tuberculosis homologue differed by 10.5% (30 bp). For the cfp-10 gene (300 bp), the observed differences varied between 0.7% (2 bp in MKA-II) and 1.3% (4 bp in genotypes MKA-IIIb, -IV, and -V), whereas the cfp-10 gene of M. tuberculosis differed by 10% (30 bp). The deduced amino acid sequences were aligned with the M. tuberculosis homologues, as is shown in figure 4A and 4B. The putative ESAT-6 and CFP-10 proteins of M. kansasii differed by only 2 or 3 and 5 or 7 amino acids, respectively, from the M. tuberculosis protein. Importantly, ESAT-6 and CFP-10 of the MKA-I and MKA-II genotypes were either identical to those of the environmental genotypes or differed by 2 aa at most. 
Figure 4
Alignment of the amino acid sequence of ESAT-6 (A) and CFP-10 (B) of Mycobacterium tuberculosis with the deduced amino acid sequences of the homologues in Mycobacterium kansasii isolates. Nos. in parentheses after the MKA genotype indicate the no. of isolates that was studied.
The clinical M. kansasii isolates of MKA-I were isolated during the period between 1991 and 2001. With regard to the nucleotide sequences of esat-6 and cfp-10, no difference was observed between isolates over time. Interestingly, the 2 water isolates from the Czech Republic that had previously been found to be MKA-I [32] showed identical MPTR RFLP and esat-6 and cfp-10 sequences as the clinical MKA-I isolates originating from The Netherlands. The clinical MKA-I strains that were isolated from patients residing in houses with the MKA-I water isolates were not included in the present study.
Expression of ESAT-6 and CFP-10 by clinical and environmental M. kansasii isolates.
Having demonstrated that there was no important difference between clinical and environmental isolates with regard to the presence of the esat-6 and cfp-10 genes or the deduced amino acid sequence of ESAT-6 and CFP-10, we next studied the expression of these genes during in vitro growth. Immunoblots of strain lysates by use of specific antibodies indicated that the ESAT-6 and CFP-10 proteins were expressed by clinical as well as environmental genotypes of M. kansasii. However, semiquantitative measurement by ECL indicated that the level of expression of ESAT-6 and CFP-10 was of a similar and high level in MKA-I and MKA-II isolates, whereas the expression of CFP-10 was relatively lower in MKA-III and MKA-IV isolates (table 3). 
DISCUSSION
In the present study, 36 clinical and environmental isolates of M. kansasii were compared with regard to the esat-6 and cfp-10 genes and gene expression. The results indicate that homologues of the esat-6 and cfp-10 genes are present in clinical and environmental isolates of M. kansasii. Southern blots showed a characteristic pattern for each genotypically defined group of isolates, which suggests either that these genes reside on different segments of the genome or that differences exist between genotypes that are associated with changes in the target site for the restriction enzyme, causing variation in fragment size. During in vitro culture, clinical isolates produced roughly equivalent amounts of ESAT-6 and CFP-10, whereas the production of ESAT-6 exceeded that of CFP-10 for some of the environmental isolates. The nucleotide sequences of esat-6 and cfp-10 of M. kansasii were determined, including a number of isolates of each genotype, to assess inter-and intragenotypic polymorphisms. Within each genotype, the sequences were identical, with the exception of a single nucleotide difference between 2 MKA-III isolates. Compared with those of the M. tuberculosis homologue, the esat-6 sequences of the M. kansasii isolates were between 10.1% and 12.6% different, but the deduced amino acid sequences of ESAT-6 were nearly identical. The cfp-10 gene and the predicted protein of M. kansasii differed slightly more from the M. tuberculosis homologue, with a difference of 10% 10.3% at the nucleotide level and 5 or 7 aa at the protein level. The deduced amino acid sequences of both ESAT-6 and CFP-10 were identical in 4 of 5 MKA genotypes, with only ESAT-6 of MKA-V and CFP-10 of MKA-IV differing from the other genotypes. Thus, on the basis of the ESAT-6 and CFP-10 sequences, no definite distinction could be made between genotypes.
The notion that genes residing within the RD1 region are required for virulence has been strengthened by the results of a number of recent studies. Deletion of the esat-6 gene in M. bovis [19] or the deletion of RD1 in M. tuberculosis has been shown to decrease virulence in experimental animal models [20] , whereas the reinsertion of RD1 into BCG or M. microti increases virulence [21] . Another study found no difference in virulence between BCG and BCG:esat-6 in mice [33] . Although the latter finding seems to contradict the results of the above-mentioned studies, the lack of virulence could be explained if both ESAT-6 and CFP-10 are required to confer virulence. The results of our study indicate that, if ESAT-6 and CFP-10 do play a role in the virulence of M. kansasii, it does not seem to be directly related to the presence of the genes, given that clinical isolates did not differ from environmental isolates in this respect and differed only partially with regard to in vitro protein expression. The functions of ESAT-6 and CFP-10 have only been partially elucidated. Two in vitro studies have found immunomodulating properties of CFP-10 on mouse mononuclear cells [34, 35] . Another study demonstrated a tight 1 : 1 molecular interaction between ESAT-6 and CFP-10, which indicates that the precise level of production of ESAT-6 relative to that of CFP-10 may be relevant for the formation of an active complex [36] . ESAT-6 and CFP-10 do not possess typical signal sequences, and the availability of a mechanism for effective secretion could be a critical factor for pathogenicity. A recent study of M. tuberculosis mutants lacking RD1, the esat-6/cfp-10 operon, or other specific RD1-encoded genes has led to a better understanding of the role played by RD1-encoded proteins in the pathogenesis of tuberculosis [37] . Secreted, but not intracellular, ESAT-6 was shown to be an important virulence factor, in that it causes cytolysis of pneumocytes. Interestingly, cfp-10, as well as several other genes in the RD1 region, were found to be involved with the secretion of ESAT-6, and a chaperone-like function would be consistent with the observed 1 : 1 molecular interaction of ESAT-6 and CFP-10. Another argument in favor of the notion that the functions of ESAT-6 and CFP-10 are closely related is that, at least in M. tuberculosis, the esat-6 and cfp-10 genes reside in the same operon and are regulated under the same promoter [13] , which would be expected to result in the expression of equal amounts of both proteins. In that regard, our observation of lower secretion of CFP-10 relative to ESAT-6 in environmental isolates of genotype MKA-III and MKA-IV, but not of MKA-II, could be relevant for the lack of virulence of the former genotypes, which are considered to be apathogenic. If our finding of differences between clinical and environmental isolates of M. kansasii with regard to protein expression can be confirmed, more extended sequencing data will be required to evaluate whether the organization of these genes in M. kansasii is different from that in M. tuberculosis.
At the start of the study, esat-6 RFLP was performed on different mycobacterial species, to validate the method. Although the results mostly confirmed previously reported data on the species distribution of esat-6, several findings were new. In 3 previous reports, the esat-6 and/or cfp-10 gene was found to be present in M. marinum, the negative isolate originating from cattle [11, 22, 23] . In our study, esat-6 was lacking in 3 of 5 M. marinum isolates, whereas cfp-10 was present in all of them. This finding could either indicate that esat-6 may not be essential for the virulence of M. marinum or, alternatively, that the esat-6 gene of some M. marinum isolates differs from the M. tuberculosis homologue to such an extent that it prevents hybridization of the probe, which will be the subject of further study. One previous study reported the absence of esat-6 in M. gordonae isolated from cattle [22] , a species that is considered to be essentially apathogenic, whereas we found positive hybridization with esat-6 in 1 of 2 isolates. This finding needs to be confirmed by PCR, to provide certainty that an esat-6 like gene is indeed present in this species. Taking these findings together, virulence does not seem to be directly related to the presence of esat-6 or cfp-10.
Although the clinical and radiological presentations of pulmonary infection with M. kansasii and M. tuberculosis are indistinguishable, clinical and epidemiological differences exist between these infections. First, extrapulmonary infection with M. tuberculosis occurs in approximately one-sixth of all patients; it results from hematogenous spread early during the course of infection, whereas extrapulmonary localization of infection with M. kansasii is rare and occurs either as localized disease after traumatic inoculation or as part of disseminated disease in immunocompromised persons. Second, there is no proof of human transmission of M. kansasii, even though patients often excrete large numbers of M. kansasii in their sputum. Another difference is that infection with M. tuberculosis is characterized by an initial latent stage in the large majority of infected persons, the duration of which varies from weeks to many decades. The lifetime risk of progression to active tuberculosis disease is estimated to be 10%. In the absence of decreased cellular immunity due to HIV infection or immunosuppressive therapy, the factors underlying reactivation are often unknown. Whether a similar latent stage of infection with M. kansasii exists has not been studied, because no validated diagnostic test is available for that purpose. For the same reason, the proportion of infected persons who develop clinical illness caused by M. kansasii is not known.
The incidence of infection with M. kansasii differs by geographic region, but, in general, it is much lower than that with M. tuberculosis. Pulmonary infection can occur in apparently healthy persons but is diagnosed most frequently in persons with structural or functional lung abnormalities, whereas disseminated infection is seen almost exclusively in immunocompromised hosts. Thus, together with the lack of human transmission, M. kansasii does not seem to be as important a threat to individual and public health as is M. tuberculosis. M. kansasii is, nevertheless, an interesting pathogen to study, because only some of the genotypes of M. kansasii are associated with clinical illness, which indicates that both virulent and avirulent strains are represented within the same species a rare characteristic in human pathogens. Detailed knowledge of the virulence factors of M. kansasii could be valuable to the understanding of the pathogenesis of mycobacterial infections in general and of tuberculosis in particular. This may aid the development of novel drugs and of an improved vaccine to target specific virulence mechanisms. In this regard, available data have indicated that vaccination with the immunodominant peptide of ESAT-6 as a subunit vaccine and with DNA containing the esat-6 gene confers partial protection against tuberculosis in mice [38, 39] . Immunization with a hybrid molecule of ESAT-6 and the immunodominant antigen 85B conferred protection against aerogenic infection with M. tuberculosis in mice at a level at least as high as BCG [40] . A recent study in guinea pigs confirmed and extended the findings in mice [41] , and effective protection was found in a nonhuman primate model [42] . Further studies of the virulence factors of M. kansasii may provide additional important data to support the ongoing battle against tuberculosis.
